Please assess the completion status of the following clinical trial:

Trial Title: TXA in Revision Total Shoulder Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients older than 18 years old~2. Patients younger than 90 years old~3. Patients undergoing scheduled revision total shoulder arthroplasty~4. Patients who consent to be randomized~Exclusion Criteria:~1. Patients younger than 18~2. Patients older than 90 years old~3. Patients who are pregnant or breast-feeding women~4. Patients who are allergic to tranexamic acid~5. Patients with proximal humerus fracture or fracture sequelae~6. Patients who use estrogen containing medications (i.e. oral contraceptive pills)~7. Patients who have acquired disturbances of color vision~8. Patients with a history of any of the following diagnosis: '~   * Subarachnoid hemorrhage~  * Active intravascular clotting~  * Severe pulmonary disease (FEV \<50% normal)~  * Plasma creatinine \> 115 μmol/L in males, \> 100 μmol/L in females, or hepatic failure)~  * (Renal impairment serum creatinine \> 1.5 times the upper limit of normal NYU)~  * Preoperative anemia \[Hemoglobin (Hb) \< 11g/dL in females, Hb \< 12 g/dL in males\]~9. Patients who refuse blood products~10. Patients undergoing hormone replacement therapy~11. Patients with diagnosed or self-reported cognitive dysfunction;~12. Patients who are unable to understand or follow instructions;~13. Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease;~14. Patients with BMI over 50~15. Any patient that the investigators feel cannot comply with all study related procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (TXA) Injection (Type: EXPERIMENTAL): Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) will receive two injections of TXA.
- Control - No Tranexamic acid (TXA) Injection (Type: NO_INTERVENTION): Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) won't receive any injections TXA.

Based on this trial design, predict the completion outcome and termination type (if applicable).